# Inhibrx claims first win for long-sought immunotherapy target

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-08 18:29 UTC · Category: Business · Sources: 9 · Current Velocity: 7.5

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Investing.com | H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy | 2026-09-08 11:36 | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxOWEI0c2hYWjViTW5nZndyeWdJaFU2Y2RnRlFBSm15cnA5cXdkU1UzZTJXYm1PMktGUWRkUkc4WE1WaEV6N3BtTUZSSThKTk9oWGRnSUdpVml2X1pOWFhQSEZxZ2I5T3kwbVVwcDNHRS0wSlN5ekhwblFVRXBMYmZNd0lBcTZhWGZoUWItdkJDVU12VlBpRDRRaTZUck5qWldCNnNKbjlpcHdPMGREM1pVZ1VhUmJTQXFPMklVeDYxVWg4UQ?oc=5) |
| Seeking Alpha | Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX) | 2026-09-08 11:36 | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxNV2FHVldPY0taMmFUUDhnMUR6X3YxbkdUQ2F6WFlRS3p4aXRwY2Qxc3RGOUw2NnNjTGE2eTI4QURzXzRfTlM3VmdyS0d0VkdvakdTQ2JTRUE4ZW5Ea2MwUGFaR3huNE9HdGhueVg0ejZTTE1iaWJlT29qdHFLNGlVUzhyT3JfbllEM242LWNhUmF5a2pPbTlZa0RvNmVYSzlLTWNtbGVQb3RySk9LQlQ4a3RodkI?oc=5) |
| PR Newswire | Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | 2026-09-08 11:36 | [Source Link](https://news.google.com/rss/articles/CBMiggJBVV95cUxQRVhiN2hIM3ZTRGlyZ2kzZnhNT1Vpd3FsVnpWN3VENEJfZUNMa1hjTi1kWDluT04zUnpPaHBVNmdjYUttdm5LM1lFUEhpRzdac2xjQU1PRGwtVjBZOW8xRG55WThaOXNHdHo2ZXJUN19BLWRGU0Z5SXMwRUJLeFlNNFVsN0pxTmZIU0J3Z3lHQWRPZDgwX2M5Sl9MNFJvOEVzUUpIcHJNTFd5MjdNOS1NNzcwWWlwM3J5TU9jamZINGhockhpWkNpYUsxYkVhLXI5YW1DMFpwZm82bVZuZkE1SXdzQWhQU1I1SUJqYzZMOXAtZmk1bkpkLUFiX1loNDdidVE?oc=5) |
| Stock Titan | Inhibrx (INBX) director buys 2,500 shares via family trust | 2026-09-08 11:36 | [Source Link](https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaXk3SmFnQkNURV9sWlpROWpQOVRMeFFyVi1nV19mUWE3NGN2TVdUZmV4azQ2SEduTjU0UlBNN21BS21RbE1hZ1dhenl2ZXJaMkpSZzdRdTdoR3Z6akE3WVp5Q2RCQTA5SGVsRExQbFdEREFSVG5IOEJKcm92eS1Yb3JJLUd3RFFINDRlQ0ZZeS1CU2JoNjdZZ3FlM05QdTRQbjQtMVY3ckt5aWlQdVpBYk9fQnhNb1ZR?oc=5) |
| Quiver Quantitative | Why Inhibrx Biosciences (INBX) Stock Is Down Today | 2026-09-08 11:36 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxNNHpjZVBpSDBTTS1MM1NvaGJHdlFkbHB5U050UHlQN1h4ZVlTdkVfaWl2Y3pHTFNnbHdIY3piTktXNDBreUt0YmZ1TzdOeDZaOTBSVEJndXhoUFdSaDZpQzBuemZnWXdmSTlBdVNVOUFuWFpfTmV0dElzYlBtMnFPcXh4SUhIc0dYUmRJODZsN1I?oc=5) |
| Newswise | Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | 2026-09-08 11:36 | [Source Link](https://news.google.com/rss/articles/CBMi4wFBVV95cUxPYmVZUmYzN29kS20zTHpFVlFhNmtfMDEzRElyQmMxYm15UklzSlZpZHQwUTQxSGlab3BuUVBwek0xNTJySDVxV0JfMXZfcFE3dEd3TG5CbnBROVluVzNzS29DZkdHTm1QSVBCUC1hZWdMbWxIYllzN2F1cHhYVmYyZWgzQ3FpODRlYTlrY1dkNE9uVXA0Wjh3RE9fYlNqbWNlajdRTE5pYUgtbTdQU0htaGNtZ3hXSXlRNGpCVmdFc0RYajJMX2FvMzBocG9pLTRtc29sY2lhal90cVFGUjU1NW9rONIB4wFBVV95cUxPYmVZUmYzN29kS20zTHpFVlFhNmtfMDEzRElyQmMxYm15UklzSlZpZHQwUTQxSGlab3BuUVBwek0xNTJySDVxV0JfMXZfcFE3dEd3TG5CbnBROVluVzNzS29DZkdHTm1QSVBCUC1hZWd) |
| Seeking Alpha | Inhibrx cancer therapy outperforms Merck’s Keytruda (INBX:NASDAQ) | 2026-09-08 11:36 | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxOcGp1Ti1BTnV2UnpBa2RKSlZPal9KYW9jRHZoaVN1N2xSUjRVR2lfVE1FZHV1WnAtS2tRWFpuMHU3VVNTR2hSVXU0TUdpcXBHVkUyLTBoSkZWS0NLa0d0VTlVQTI1dHdJak8ydkFEOFZRVUM5N0tSV0FzdVBkU0llTDMyTDRUVFdOd3B3dWlSUU5JQQ?oc=5) |
| endpoints.news | Inhibrx opens door to cancer vaccine combo for its OX40 agonist | 2026-09-08 11:36 | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxQT3FJc1NVbUM4Q0liRGx4MmdneFZyWDNzdDJFOEhlUVVNRjAyalMwM0lRTG5WMFJYbmFhNUFpYmJPQmdMaExwTmNCR3FiN1ltMGJvNnZZWjJiZkFad1NTQVQxejFxaHFNZTNnaFBpcm5zUFk1WUdxaHVOa1hTYUUwQmFJeWg5SEhOdU1DRmo0dGdNQnZsYVNyWFdR?oc=5) |
| Fierce Biotech | Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability | 2026-09-08 11:36 | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxNR2tGcG1vVExfN3phOFZGM1lZNjUteHlUYUM0WTRyME9Td1dBUWctaWtpd1RnRkVEQjVEaFUyUkZDcE1xelgwYUY3QU9KU3JGejlNMzVoQmxJYjVqWTVhTHh6TWdOSDdpOVlxd3g5MG5hVkFhSlRjeXhRQWtVOWtTSTl2UWtfVUtEaDEwYmpLdUJ3VEFYS05pQndqNFRPd2lHVGxBOEoxTFJ5ZmxraFJB?oc=5) |
| STAT | Inhibrx claims first win for long-sought immunotherapy target | 2026-09-08 11:36 | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT3BoTWlpNmlrNXF3M01ZM0llYWtORmJvR2l6TE9lcDlzeGZmQ1ZUWXVHTUVZZnRhV3Q0TThsODM0OE5sRk5fS2ZRU2kwcnhrb1hZSGJ1Y00tZ1NkYTdjdzlFUVdranRZYTVFc3NXeWpsQVc2WFRBbk9JZjI5YmFpRExDYkNQTGJpMVpKLU5HWWRneWZZOUNUdnlVNTlzdmRlRDUwQnBqTDlwcU0?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-08/inhibrx-claims-first-win-for-long-sought-immunotherapy-target*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*